Catheter Precision (VTAK) Net Income towards Common Stockholders (2017 - 2026)

Catheter Precision (VTAK) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$3.0 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$3.0 million, up 24.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$14.3 million (up 38.32% YoY), and the FY2025 annual result was -$17.2 million, up 21.18% from the prior year.
• Net Income towards Common Stockholders slipped to -$3.0 million in Q1 2026 per VTAK's latest filing, from -$2.7 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$669000.0 in Q4 2023 and troughed at -$67.2 million in Q1 2023.
• A 5-year average of -$8.1 million and a median of -$4.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 96.02% in 2024 and fell as far as 1512.26% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$8.2 million in 2022, then surged by 91.8% to -$669000.0 in 2023, then tumbled by 1512.26% to -$10.8 million in 2024, then jumped by 75.38% to -$2.7 million in 2025, then declined by 14.5% to -$3.0 million in 2026.
• Business Quant data shows VTAK's Net Income towards Common Stockholders at -$3.0 million in Q1 2026, -$2.7 million in Q4 2025, and -$2.2 million in Q3 2025.